These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
199 related items for PubMed ID: 1746455
1. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group. Kirshenbaum JM, Bahr RD, Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher RR, Topol EJ, Wahr DW, Braunwald E. Am J Cardiol; 1991 Dec 15; 68(17):1564-9. PubMed ID: 1746455 [Abstract] [Full Text] [Related]
2. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. Collen D, Van de Werf F. Am J Cardiol; 1987 Sep 01; 60(7):431-4. PubMed ID: 3115077 [Abstract] [Full Text] [Related]
3. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V. J Am Coll Cardiol; 1995 Aug 01; 26(2):374-9. PubMed ID: 7608437 [Abstract] [Full Text] [Related]
7. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis]. Motomiya T. Nihon Rinsho; 2003 Apr 01; 61 Suppl 4():441-5. PubMed ID: 12735012 [No Abstract] [Full Text] [Related]
8. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase. Tebbe U, Windeler J, Boesl I, Hoffmann H, Wojcik J, Ashmawy M, Rüdiger Schwarz E, von Loewis P, Rosemeyer P, Hopkins G. J Am Coll Cardiol; 1995 Aug 01; 26(2):365-73. PubMed ID: 7608436 [Abstract] [Full Text] [Related]
11. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Van de Werf F, Vanhaecke J, de Geest H, Verstraete M, Collen D. Circulation; 1986 Nov 01; 74(5):1066-70. PubMed ID: 2429783 [Abstract] [Full Text] [Related]
18. [New thrombolytic agents in myocardial infarction]. Charbonnier B, Lang M, Brochier M. Arch Mal Coeur Vaiss; 1987 Nov 01; 80(12):1785-91. PubMed ID: 3128222 [Abstract] [Full Text] [Related]
19. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Badylak SF, Voytik S, Klabunde RE, Henkin J, Leski M. Thromb Res; 1988 Nov 15; 52(4):295-312. PubMed ID: 3144052 [Abstract] [Full Text] [Related]
20. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A. Circulation; 1995 Jun 01; 91(11):2725-32. PubMed ID: 7758177 [Abstract] [Full Text] [Related] Page: [Next] [New Search]